There are currently 176 clinical trials in Saint Paul, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including United Hospital, Regions Hospital, Regions Hospital Cancer Care Center and Gilette Children's Speciality Healthcare. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Health Partners Cancer Center at Regions Hospital, Saint Paul, Minnesota
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: HealthEast Medical Research Institute, Saint Paul, Minnesota
Conditions: Acute Coronary Syndrome
Register for Updates
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334
Recruiting
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT05206513
Recruiting
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
Gender:
ALL
Ages:
Between 6 years and 70 years
Trial Updated:
05/21/2025
Locations: Neurocrine Clinical Site, Saint Paul, Minnesota
Conditions: Dyskinesia, Cerebral Palsy
Register for Updates
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05646316
Recruiting
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Allina Health Cancer Institute - United Hospital, Saint Paul, Minnesota
Conditions: Breast Cancer
Register for Updates
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: HealthPartners Cancer Research Center, Saint Paul, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651
Recruiting
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Colorectal Neoplasms
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Urothelial Carcinoma
Register for Updates
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
NCT05008848
Recruiting
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Cigarette Smoking-Related Carcinoma
Register for Updates
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574
Recruiting
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma, Head and Neck Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Urinary System Mucosal Melanoma
Register for Updates